For a study, researchers examined the blood levels and clinical importance of interleukin 1β (IL-1β) and interleukin 6 (IL-6) in children with hyperuricemia (HUA). As control subjects, researchers included 71 children with HUA and 71 children without HUA. Children with HUA were classified into two groups based on whether they had a history of acute gout-like events (including sudden monoarthritis of rapid onset with intense pain and swelling). Group, I was tested twice (A, in the acute phase; B, in the remission phase). The enzyme-linked immunosorbent assay was used to determine the levels of IL-1β and IL-6 in the blood.
Serum IL-1β and IL-6 levels were higher in HUA children and were significantly different from the control group (P< 0.05, respectively). Serum IL-1β and IL-6 levels were substantially greater in group IA than in groups IB, II, and control participants (P <0.05), as well as in groups IB and II than in control subjects (P< 0.05). Although blood IL-1β and IL-6 concentrations in group IB were greater than in group II, no substantial differences (P > 0.05) were found. Furthermore, serum IL-1β and IL-6 levels were positively associated with white blood cell count, neutrophil count, monocyte count, uric acid levels, erythrocyte sedimentation rate, C-reactive protein, blood urea nitrogen, and serum creatinine levels in children with HUA (all P <0.05), but not with triglycerides, total cholesterol, low-density lipoprotein cholesterol, or high-density lipoprotein cholesterol (all P > 0.05).
Even if a child did not have acute gout, IL-1β and IL-6 levels were elevated in children with hyperuricemia. More research was required to properly assess the importance of the IL-1β and IL-6 levels reported in HUA youngsters, as well as whether they were connected to long-term prognosis.
